KDMN On Other Exchanges
Symbol
Exchange
New York
Frankfurt

kadmon holdings inc (KDMN) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KADMON HOLDINGS INC (KDMN)
\

Related News

No related news articles were found.

kadmon holdings inc (KDMN) Related Businessweek News

No Related Businessweek News Found

kadmon holdings inc (KDMN) Details

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington’s disease. Its lead product candidates include KD025, an inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical studies for the treatment of chronic graft-versus-host, fibrotic, and psoriasis diseases; KD045, an ROCK inhibitor for the treatment of fibrotic diseases; KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer; and KD034, a generic formulation of trientine hydrochloride for the treatment of Wilson’s disease, a genetic liver disease. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease (PKD) and autosomal recessive PKD. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Zydus Pharmaceuticals USA, Inc.; and Jinghua Pharmaceutical Group Co., Ltd. The company is headquartered in New York, New York.

116 Employees
Last Reported Date: 03/7/19

kadmon holdings inc (KDMN) Top Compensated Officers

President, CEO & Director
Total Annual Compensation: $1.1M
Executive VP & CFO
Total Annual Compensation: $37.5K
Chief Administrative, Compliance & Legal Offi...
Total Annual Compensation: $634.5K
Compensation as of Fiscal Year 2018.
kadmon holdings inc
Kadmon Holdings, Inc. Presents at Jefferies 2019 Healthcare Conference, Jun-05-2019 11:30 AM

Kadmon Holdings, Inc. Presents at Jefferies 2019 Healthcare Conference, Jun-05-2019 11:30 AM. Venue: Grand Hyatt, 109 E 42nd St, New York, New York, United States. Speakers: Harlan W. Waksal, President, CEO & Director.

Kadmon Holdings, Inc. Approves Appointment of Arthur Kirsch to Board of Directors

Kadmon Holdings, Inc. announced that Arthur Kirsch at Annual Meeting of Stockholders on May 15, 2019 was elected to the Company’s Board of Directors to hold office for terms to expire in one year or until their successors are elected and qualified.

Kadmon Holdings, Inc. Announces Amendment to the Certificate of Incorporation

Kadmon Holdings, Inc. announced amendment to the Certificate of Incorporation of the Corporation, and declaring said amendment to be advisable. The stockholders of the Corporation duly approved said proposed amendment in accordance with Section 242 of the General Corporation Law of the State of Delaware. The resolution setting forth the amendment is that the first paragraph of Article IV of the Certificate of Incorporation of the Corporation be and hereby is deleted in its entirety and the following is inserted in lieu thereof: The total number of shares of capital stock of all classes which the Corporation shall have authority to issue is 410,000,000 shares, consisting of: 400,000,000 shares of common stock, $0.001 par value per share and 10,000,000 shares of preferred stock, par value $0.001 per share.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

KDMN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KDMN.
View Industry Companies
 

Industry Analysis

KDMN

Industry Average

Valuation KDMN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 213.2x
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 28.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact KADMON HOLDINGS INC, please visit www.kadmon.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.